Theravance Biopharma shares plunge 26% after drug trial failure triggers strategic review [Yahoo! Finance]
Theravance Biopharma, Inc. - Ordinary Shares (TBPH)
Last theravance biopharma, inc. - ordinary shares earnings: 2/24 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.theravance.com/investor-relations
Company Research
Source: Yahoo! Finance
Theravance Biopharma shares plunge 26% after drug trial failure triggers strategic review Proactive uses images sourced from Shutterstock The company is working with Lazard on a potential sale after its lead drug candidate disappointed in a late-stage study Theravance Biopharma shares collapsed 26% in morning trading on Tuesday after the company said it was exploring a potential sale following the failure of its most advanced drug candidate in a late-stage clinical trial. The company said ampreloxetine, which was being tested in patients with multiple system atrophy, a rare and progressive neurological condition that can cause a dangerous fall in blood pressure upon standing, failed to demonstrate a meaningful improvement in symptoms compared with patients receiving a placebo. The disorder, known medically as neurogenic orthostatic hypotension when it causes blood pressure to drop on standing, represents a significant unmet medical need, and the drug had been seen as Theravan
Show less
Read more
Impact Snapshot
Event Time:
TBPH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TBPH alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TBPH alerts
High impacting Theravance Biopharma, Inc. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
TBPH
News
- Theravance Biopharma (TBPH) was downgraded by Oppenheimer Holdings, Inc. from "outperform" to "market perform".MarketBeat
- Theravance Biopharma (TBPH) had its "neutral" rating reaffirmed by B. Riley Financial, Inc.. They now have a $14.00 price target on the stock, down from $28.00.MarketBeat
- Theravance shuts down R&D efforts and cuts workforce by half after Phase III trial failure [Yahoo! Finance]Yahoo! Finance
- The Excruciating Failure That Could Cause Theravance, Down 27%, To Sell Itself [Yahoo! Finance]Yahoo! Finance
- Theravance Biopharma (TBPH) had its price target lowered by BTIG Research from $40.00 to $21.00. They now have a "buy" rating on the stock.MarketBeat
TBPH
Earnings
- 11/10/25 - Beat
TBPH
Sec Filings
- 3/3/26 - Form 8-K
- 2/24/26 - Form 4
- 2/24/26 - Form 4
- TBPH's page on the SEC website